Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CVM logo CVM
Upturn stock ratingUpturn stock rating
CVM logo

CEL-SCI Corp (CVM)

Upturn stock ratingUpturn stock rating
$2.29
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: CVM (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $240.02

1 Year Target Price $240.02

Analysts Price Target For last 52 week
$240.02Target price
Low$1.98
Current$2.29
high$47.7

Analysis of Past Performance

Type Stock
Historic Profit -26.63%
Avg. Invested days 15
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 12.32M USD
Price to earnings Ratio -
1Y Target Price 240.02
Price to earnings Ratio -
1Y Target Price 240.02
Volume (30-day avg) 1
Beta 0.26
52 Weeks Range 1.98 - 47.70
Updated Date 06/29/2025
52 Weeks Range 1.98 - 47.70
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -12.3

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -62.86%
Return on Equity (TTM) -244.56%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 20931190
Price to Sales(TTM) 11797.42
Enterprise Value 20931190
Price to Sales(TTM) 11797.42
Enterprise Value to Revenue -
Enterprise Value to EBITDA -3.71
Shares Outstanding 5135020
Shares Floating 2997739
Shares Outstanding 5135020
Shares Floating 2997739
Percent Insiders 1.2
Percent Institutions 5.07

Analyst Ratings

Rating 1
Target Price 240.02
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

CEL-SCI Corp

stock logo

Company Overview

overview logo History and Background

CEL-SCI Corp is a biotechnology company focused on researching and developing immune system-based therapies for the treatment of cancer and other diseases. Founded in 1983, the company has primarily focused on its lead investigational therapy, Multikine.

business area logo Core Business Areas

  • Immunotherapy Development: Focused on the development and commercialization of cancer immunotherapies, primarily Multikine (Leukocyte Interleukin, Injection) for the treatment of head and neck cancer.

leadership logo Leadership and Structure

Geert Kersten serves as the Chief Executive Officer of CEL-SCI Corp. The company operates with a standard corporate structure, including a board of directors and various departments focused on research and development, clinical trials, and regulatory affairs.

Top Products and Market Share

overview logo Key Offerings

  • Multikine (Leukocyte Interleukin, Injection): Multikine is CEL-SCI's lead investigational therapy, designed as a neoadjuvant immunotherapy for treatment-naive advanced primary head and neck cancer. It is not yet approved. Competitors include Merck (Keytruda), Bristol Myers Squibb (Opdivo), and various chemotherapy regimens.

Market Dynamics

industry overview logo Industry Overview

The biotechnology industry is characterized by intense competition, high research and development costs, and a complex regulatory environment. Cancer immunotherapy is a rapidly growing field with significant potential.

Positioning

CEL-SCI is positioned as a company focused on developing novel immunotherapy treatments for cancer. Their competitive advantage, if proven effective, would lie in Multikine's novel approach and potential to improve patient outcomes. Their clinical trial data remains under scrutiny.

Total Addressable Market (TAM)

The global head and neck cancer market is projected to reach billions of dollars. CEL-SCI aims to capture a portion of this market with Multikine, if approved.

Upturn SWOT Analysis

Strengths

  • Proprietary immunotherapy technology
  • Experienced management team
  • Focused on unmet medical needs

Weaknesses

  • Limited financial resources
  • Reliance on a single product candidate (Multikine)
  • Past clinical trial setbacks and controversies
  • No FDA approved products

Opportunities

  • Potential FDA approval of Multikine
  • Expansion into other cancer indications
  • Partnerships with larger pharmaceutical companies

Threats

  • Regulatory hurdles and clinical trial failures
  • Competition from established pharmaceutical companies
  • Patent expiration
  • Adverse reactions from Multikine

Competitors and Market Share

competitor logo Key Competitors

  • MRK
  • BMY
  • PFE

Competitive Landscape

CEL-SCI faces significant competition from large pharmaceutical companies with established immunotherapy products and greater resources. Its success depends on demonstrating a clear clinical benefit with Multikine.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been primarily driven by investment in research and development, with no significant product revenue to date.

Future Projections: Future growth is contingent on the successful development and commercialization of Multikine or other pipeline candidates. Analyst projections are speculative and highly dependent on regulatory approvals.

Recent Initiatives: Recent initiatives have focused on addressing regulatory inquiries and seeking potential partnerships.

Summary

CEL-SCI Corp is a high-risk, high-reward biotechnology company focused on developing Multikine. Its future hinges on successful clinical trials and regulatory approval. The company's lack of product revenue and reliance on a single candidate presents significant risks. Strong strategic partnerships or acquisition may be key to long-term viability.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC filings
  • Company website
  • Third-party financial data providers
  • Industry reports

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About CEL-SCI Corp

Exchange NYSE MKT
Headquaters Vienna, VA, United States
IPO Launch date 1987-01-01
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees -
Full time employees -

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.